GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Healthways, Inc. (HWAY) [hlAlert]

Rating:
Buy HWAY
down 1.80 %

Healthways, Inc. (HWAY) upgraded to Buy with price target $15 by Dougherty & Company

Posted on: Friday,  Jun 19, 2015  12:25 PM ET by Dougherty & Company

Dougherty & Company rated Buy Healthways, Inc. (NASDAQ: HWAY) on 06/19/2015, when the stock price was $12.16.
Since then, Healthways, Inc. has lost 1.81% as of 12/31/2015's recent price of $11.94.
If you would have followed this Dougherty & Company 's recommendation on HWAY, you would have lost 1.8% of your investment in 195 days.

Healthways, Inc. provides specialized health and care support solutions in the United States. Its services include fostering wellness and disease prevention through total population screening, health risk assessments, and supportive interventions; providing access to health improvement programs, such as fitness, weight management, complementary and alternative medicine, and smoking cessation; promoting the reduction of lifestyle behaviors that lead to poor health or chronic conditions; and providing educational materials and personal interactions with trained nurses and other healthcare professionals that are designed to create and sustain healthier behaviors to members with chronic conditions. The company's services also comprise incorporating current evidence-based clinical guidelines into interventions to optimize patient health outcomes; developing care support plans providing local market resources to address acute episodic interventions; and coordinating members' care with local healthcare providers. Healthways also offers Care Support product line, which consist of programs for people with chronic diseases or conditions, including diabetes, coronary artery disease, heart failure, asthma, chronic obstructive pulmonary disease, end-stage renal disease, cancer, chronic kidney disease, depression, high-risk obesity, metabolic syndrome, acid-related stomach disorders, atrial fibrillation, decubitus ulcer, fibromyalgia, hepatitis C, inflammatory bowel disease, irritable bowel syndrome, low-back pain, osteoarthritis, osteoporosis, and urinary incontinence. In addition, it provides high-risk care management through its StatusOne product for members at risk for hospitalization due to complex conditions. The company was founded in 1981 and is headquartered in Nashville, Tennessee.

Team The research group is composed of five senior analysts and two associate analysts. The senior analysts collectively have 44 years of securities industry experience, and include 3 MBA's, 2 CPA's, 2 PE's (professional engineer), a CFA and a CMA. The team has come together out of a passion for overlooked or misunderstood investment opportunities – generally in smaller-cap companies – and a love of in-depth research, with special emphasis on independent information sources and innovative thinking. Coverage Our research coverage is idea driven and balances the twin demands of opportunism for flexibility and universe consistency for maximization of information sources. Current sub-sectors of interest include: * Specialty retail * Internet security * Internet media * Auto-identification and data capture (AIDC & RFID) * Mobile computing * Specialty manufacturing * Chronic care management * Outpatient services * Medical devices * Healthcare IT
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/19/2015 12:25 PM Buy
None
12.16 15.00
as of 8/27/2015
1 Week down  -5.91 %
1 Month down  -2.21 %
3 Months down  -1.80 %
1 YTD down  -9.68 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/14/2014 1:25 PM Hold
None
14.14
2/8/2013 10:25 AM Buy
None
10.50 16.00
5/7/2012 10:25 AM Buy
None
6.73 12.00
10/25/2011 4:25 PM Hold
None
6.37 12.00
2/18/2010 10:25 AM Buy
None
15.86 24.00
2/11/2009 9:25 AM Buy
None
11.54 17.00
2/6/2009 9:25 AM Buy
None
11.26 18.00
8/26/2008 10:25 AM Buy
None
19.53 25.00
2/27/2008 11:25 AM Buy
None
32.70 50.00
10/18/2007 1:25 PM Buy
None
56.14 75.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy